Shanghai RAAS Blood Products Co Ltd Class A
Shanghai RAAS Blood Products Co., Ltd. engages in the manufacture and sale of blood products in China. It offers human serum albumin, human intravenous immunoglobulin, human coagulation factor VIII, human prothrombin complex, human fibrinogen, human thrombin and human fibrin adhesive, human immunoglobulin, hepatitis B immunoglobulin, tetanus immunoglobulin, and rabies immunoglobulin products. The… Read more
Shanghai RAAS Blood Products Co Ltd Class A (002252) - Total Liabilities
Latest total liabilities as of September 2025: CN¥5.44 Billion CNY
Based on the latest financial reports, Shanghai RAAS Blood Products Co Ltd Class A (002252) has total liabilities worth CN¥5.44 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Shanghai RAAS Blood Products Co Ltd Class A - Total Liabilities Trend (2005–2024)
This chart illustrates how Shanghai RAAS Blood Products Co Ltd Class A's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Shanghai RAAS Blood Products Co Ltd Class A Competitors by Total Liabilities
The table below lists competitors of Shanghai RAAS Blood Products Co Ltd Class A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Havells India Limited
NSE:HAVELLS
|
India | ₹49.60 Billion |
|
Petrobras Distribuidora S.A
PINK:PETRY
|
USA | $41.23 Billion |
|
Guangzhou Haige Communications Group Incorporated Co
SHE:002465
|
China | CN¥8.54 Billion |
|
Zhongfu Shenying Carbon Fiber Co. Ltd. A
SHG:688295
|
China | CN¥4.73 Billion |
|
MRF Limited
NSE:MRF
|
India | ₹108.79 Billion |
|
Lynas Rare Earths Ltd
PINK:LYSCF
|
USA | $630.28 Million |
|
Omv Petrom S.A
RO:SNP
|
Romania | RON19.45 Billion |
Liability Composition Analysis (2005–2024)
This chart breaks down Shanghai RAAS Blood Products Co Ltd Class A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.37 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shanghai RAAS Blood Products Co Ltd Class A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shanghai RAAS Blood Products Co Ltd Class A (2005–2024)
The table below shows the annual total liabilities of Shanghai RAAS Blood Products Co Ltd Class A from 2005 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.69 Billion | -25.81% |
| 2023-12-31 | CN¥2.28 Billion | +38.55% |
| 2022-12-31 | CN¥1.64 Billion | +23.43% |
| 2021-12-31 | CN¥1.33 Billion | +266.31% |
| 2020-12-31 | CN¥363.74 Million | +0.49% |
| 2019-12-31 | CN¥361.95 Million | -26.91% |
| 2018-12-31 | CN¥495.18 Million | -74.93% |
| 2017-12-31 | CN¥1.98 Billion | +32.10% |
| 2016-12-31 | CN¥1.50 Billion | +77.24% |
| 2015-12-31 | CN¥843.64 Million | +11.72% |
| 2014-12-31 | CN¥755.16 Million | +59.53% |
| 2013-12-31 | CN¥473.37 Million | +150.74% |
| 2012-12-31 | CN¥188.79 Million | +129.51% |
| 2011-12-31 | CN¥82.26 Million | -17.01% |
| 2010-12-31 | CN¥99.12 Million | +60.16% |
| 2009-12-31 | CN¥61.88 Million | -19.03% |
| 2008-12-31 | CN¥76.42 Million | -44.02% |
| 2007-12-31 | CN¥136.53 Million | -18.92% |
| 2006-12-31 | CN¥168.39 Million | +65.20% |
| 2005-12-31 | CN¥101.93 Million | -- |